Stock ISKJ HUMAN STEM CELLS INSTITUTE
Add to a list
To use this feature you must be a member
Log inSign up

Financials Human Stem Cells Institute

Equities

ISKJ

RU000A0JNAB6

Healthcare Facilities & Services

End-of-day quote Moscow Micex - RTS
Other stock markets
 06:00:00 2022-07-07 pm EDT 		5-day change 1st Jan Change
59.54 RUB +1.43% Intraday chart for Human Stem Cells Institute -.--% -.--%
Apr. 26 Artgen Biotech PJSC Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 Artgen Biotech PJSC Reports Earnings Results for the Half Year Ended June 30, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 568 935.2 2,747 8,272 4,287 4,419
Enterprise Value (EV) 1 747.1 1,181 3,128 8,695 4,891 4,661
P/E ratio -17.3 x 11.5 x 39.3 x 790 x 112 x 32.7 x
Yield - - - - 1.68% -
Capitalization / Revenue 0.88 x 1.12 x 2.53 x 7.01 x 3.77 x 3.23 x
EV / Revenue 1.16 x 1.41 x 2.89 x 7.36 x 4.3 x 3.41 x
EV / EBITDA 5.1 x 5.28 x 12.5 x 46.1 x 28.4 x 13.5 x
EV / FCF 4.59 x -9.68 x -145 x -708 x -42 x -82 x
FCF Yield 21.8% -10.3% -0.69% -0.14% -2.38% -1.22%
Price to Book 21.9 x 9.87 x 14.7 x 41.6 x 14.2 x 11.1 x
Nbr of stocks (in thousands) 71,994 71,994 71,994 71,994 71,994 74,225
Reference price 2 7.890 12.99 38.16 114.9 59.54 59.54
Announcement Date 4/29/19 5/10/20 4/30/21 5/5/22 5/2/23 4/26/24
1RUB in Million2RUB
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 644.7 835.6 1,084 1,181 1,137 1,369
EBITDA 1 146.4 223.8 250.8 188.8 172.4 346.4
EBIT 1 117.4 180.5 198 130.4 133.8 275.5
Operating Margin 18.21% 21.6% 18.26% 11.05% 11.77% 20.13%
Earnings before Tax (EBT) 1 -53.83 101.4 93.47 29.46 29.3 211.4
Net income 1 -34.21 84.55 72.85 11.63 46.12 168.9
Net margin -5.31% 10.12% 6.72% 0.99% 4.06% 12.34%
EPS 2 -0.4561 1.127 0.9700 0.1454 0.5300 1.820
Free Cash Flow 1 162.7 -122.1 -21.61 -12.27 -116.6 -56.85
FCF margin 25.24% -14.61% -1.99% -1.04% -10.26% -4.15%
FCF Conversion (EBITDA) 111.13% - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - 1.000 -
Announcement Date 4/29/19 5/10/20 4/30/21 5/5/22 5/2/23 4/26/24
1RUB in Million2RUB
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 179 246 381 423 605 242
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) 1.223 x 1.099 x 1.517 x 2.242 x 3.506 x 0.6986 x
Free Cash Flow 1 163 -122 -21.6 -12.3 -117 -56.9
ROE (net income / shareholders' equity) -14.6% 45.2% 26.3% 7.66% 4.48% 25.2%
ROA (Net income/ Total Assets) 6.74% 8.94% 8.5% 5.02% 4.42% 7.51%
Assets 1 -507.7 945.7 857 231.8 1,043 2,250
Book Value Per Share 2 0.3600 1.320 2.590 2.760 4.180 5.390
Cash Flow per Share 2 0.8600 1.200 1.430 2.270 2.470 5.870
Capex 1 35.3 196 85.6 153 136 204
Capex / Sales 5.48% 23.48% 7.9% 12.98% 11.96% 14.93%
Announcement Date 4/29/19 5/10/20 4/30/21 5/5/22 5/2/23 4/26/24
1RUB in Million2RUB
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Healthcare Facilities & Services

1st Jan change Capi.
HUMAN STEM CELLS INSTITUTE Stock Human Stem Cells Institute
-.--% 47.99M
CVS HEALTH CORPORATION Stock CVS Health Corporation
-14.58% 84.68B
HCA HEALTHCARE, INC. Stock HCA Healthcare, Inc.
+15.05% 81.12B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY Stock Dr. Sulaiman Al Habib Medical Services Group Company
+10.49% 29.59B
LABORATORY CORPORATION OF AMERICA HOLDINGS Stock Laboratory Corporation of America Holdings
-10.17% 16.73B
FRESENIUS SE & CO. KGAA Stock Fresenius SE & Co. KGaA
-1.39% 16.36B
PURE HEALTH HOLDING Stock Pure Health Holding
-31.58% 11.77B
FRESENIUS MEDICAL CARE AG Stock Fresenius Medical Care AG
+1.82% 11.72B
DAVITA INC. Stock DaVita Inc.
+31.86% 11.71B
EUROFINS SCIENTIFIC SE Stock Eurofins Scientific SE
-0.47% 11.66B
Other Healthcare Facilities & Services
  1. Stock Market
  2. Equities
  3. ISKJ Stock
  4. Financials Human Stem Cells Institute